Results 51 to 60 of about 780 (113)

Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure. [PDF]

Front Immunol, 2022
Lin X, Song A, Lu J, Zheng S, Hu Z, Ma L, Cao Z, Li H, Zheng Y, Ren S, Chen X.   +10 more
europepmc   +1 more source

Defining success in functional cure for chronic hepatitis B: a nationwide survey of physician benchmarks to guide clinical practice and trial design. [PDF]

Front Public Health
Ren S, Liu Y, Lin X, Lu J, Ma L, Zheng S, Chen X.   +6 more
europepmc   +1 more source

Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study. [PDF]

J Virus Erad
Wang YH, Tao YC, Wang ML, Song CR, Peng JN, Chen EQ.   +5 more
europepmc   +1 more source

A comparison of counter-immunoelectrophoresis, reversed haemagglutination and radioimmunoassay for the detection of HBsAg in blood donors.

Haematologica, 1975
G, Angeloni, L, D'Antoni
openaire   +1 more source

Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in Asians with Chronic Hepatitis B Virus Infection. [PDF]

Gastro Hep Adv
Lau W, Drysdale M, Morais E, Antunes L, Mak L, Lee C, Camarinha C, Sun X, Chan AYL, Lam M, Gielen V, Theodore D, Wong ICK, Gillespie IA.   +13 more
europepmc   +1 more source

Clinical outcomes after HBsAg clearance in chronic hepatitis B patients treated with Peg-IFN α: A study with an 11- to 173-month follow-up. [PDF]

Virol Sin
Deng W, Hao H, Zhang Z, Li X, Cao W, Zhang Y, Wang S, Gao Z, Yao L, Wang S, Wei X, Yi W, Zhao L, Xie Y, Li M.   +14 more
europepmc   +1 more source

Functional immune responses induced by a capsid assembly modulator in chronic hepatitis B virus-infected humanized mice. [PDF]

Cell Host Microbe
Fernandes P, Wang Y, Doisne JM, Thaller A, Fiquet O, Dailleux R, Amblard F, Testoni B, Aronthippaitoon Y, Mouquet H, Sureau C, Reyné B, Tiezzi C, Soussan P, Levrero M, Zoulim F, Schinazi RF, Strick-Marchand H.   +17 more
europepmc   +1 more source

Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy. [PDF]

AIDS
Mezzadri L, Soria AG, Ranzani A, Malandrin S, Sabbatini F, Limonta S, Cappelletti A, Colella E, Squillace N, Caramma ICG, Monti B, Rugova A, Cavallero A, Bonfanti P, Lapadula G.   +14 more
europepmc   +1 more source

Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0. [PDF]

Clin Mol Hepatol
Wu D, Kao JH, Piratvisuth T, Wang X, Kennedy PTF, Otsuka M, Ahn SH, Tanaka Y, Wang G, Yuan Z, Li W, Lim YS, Niu J, Lu F, Zhang W, Gao Z, Kaewdech A, Han M, Yan W, Ren H, Hu P, Shu S, Kwo PY, Wang FS, Yuen MF, Ning Q.   +25 more
europepmc   +1 more source

Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy. [PDF]

Hepatol Forum
Dilber F, Durak S, Unsal Y, Demir M, Yildirim AE, Ellik ZM, Mehdiyev S, Adanir H, Yapali S, Demirtas CO, Ucbilek E, Balaban Y, Ekmen N, Gokcan H, Koc ES, Dincer D, Sezgin O, Simsek H, Tozun N, Arslan M, Idilman R, Etik DO, Gokcen P, Ari D, Ozdil K, Akdogan M, Boyacioglu S.   +26 more
europepmc   +1 more source